Leerink downgraded Merus (MRUS) to Market Perform from Outperform with a $97 price target after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Unusually active option classes on open October 2nd
- Balanced Hold Rating Amid Genmab’s Acquisition of Merus and Anticipated CRC Data
- Hold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
- Merus downgraded to Neutral from Buy at UBS
- Merus downgraded to Market Perform from Outperform at BMO Capital